InMed Pharmaceuticals Inc (INM)
0.291
-0.01
(-3.32%)
USD |
NASDAQ |
Apr 19, 09:35
InMed Pharmaceuticals Revenue (Quarterly): 1.240M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.240M |
| September 30, 2023 | 0.9019M |
| June 30, 2023 | 2.311M |
| March 31, 2023 | 1.034M |
| December 31, 2022 | 0.4698M |
| September 30, 2022 | 0.3208M |
| June 30, 2022 | 0.5148M |
| March 31, 2022 | 0.3096M |
| December 31, 2021 | 0.2651M |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 |
| Date | Value |
|---|---|
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 | |
| December 31, 2011 | |
| September 30, 2011 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.2651M
Minimum
Dec 2021
2.311M
Maximum
Jun 2023
0.8186M
Average
0.5148M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| Rimrock Gold Corp | -- |
| Venus Concept Inc | 18.13M |
| Juva Life Inc | 1.725M |
| CEN Biotech Inc | 0.0941M |
| Lucy Scientific Discovery Inc | 0.0097M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.478M |
| Total Expenses (Quarterly) | 2.945M |
| EPS Diluted (Quarterly) | -0.19 |
| Enterprise Value | -7.711M |
| Gross Profit Margin (Quarterly) | 26.14% |
| Profit Margin (Quarterly) | -119.2% |
| Earnings Yield | -436.4% |
| Normalized Earnings Yield | -435.76 |